Top in ID: Safety of COVID-19 boosters, social media in medicine
Click Here to Manage Email Alerts
Last week’s top story in infectious disease was about new data on the safety of a third dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines, which revealed “no unexpected patterns of adverse reactions,” researchers reported.
Another top story was about the importance of social media for medical professionals in promoting their work, networking and educating others. Kelly Cawcutt, MD, MS, said that a major component of social media is creating an appropriate personal brand.
Read these and more news in infectious disease, including highlights from the virtual IDWeek conference, below:
‘No unexpected patterns of adverse reactions’ among thousands who received third shot
Researchers reported in MMWR that a third dose of a COVID-19 mRNA vaccine appeared to be safe in thousands of Americans who received it. Read more.
Social media ‘has the capacity to revolutionize medicine’
During this year’s Women in Medicine Summit, Cawcutt discussed the importance of properly using social media to network, promote important work and educate anyone willing to engage, saying it can “revolutionize medicine.” Read more.
CYPRESS trial: RSV vaccine effective in older adults
An investigational respiratory syncytial virus vaccine was safe and effective against RSV-mediated lower respiratory tract disease among older adults, according to results from a phase 2 randomized controlled study called CYPRESS. Read more.
C. difficile prevalent in non-health care settings — especially on shoes
Global surveillance of Clostridioides difficile showed that it was widely prevalent among isolates collected outside of health care settings — especially on the soles of shoes, according to researchers at IDWeek. Read more.
Remdesivir reduces risk for COVID-19 hospitalization in high-risk patients
A 3-day course of IV remdesivir was safe, well tolerated and prevented COVID-19-related hospitalizations among high-risk COVID-19 patients, according to data presented at IDWeek. Read more.